Leuprolide Research: What 4,009 Studies Show (2026) | RetatrutideCompare

Leuprolide — 4,009 studies indexed on PubMed. GnRH receptor super-agonist. Continuous receptor activation downregulates GnRH receptors after initial flare, suppressing LH/FSH. Half-life: ~3 hours (depot formulations release over 1-6 months). FDA status: FDA-approved (1985).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Leuprolide?

There are approximately 4,009 studies indexed on PubMed that mention Leuprolide (Lupron, Eligard), based on a search last updated 2026-06-18.

Is Leuprolide FDA-approved?

FDA status: FDA-approved (1985).

How does Leuprolide work?

GnRH receptor super-agonist. Continuous receptor activation downregulates GnRH receptors after initial flare, suppressing LH/FSH.

Reference facts

Also known as: Lupron, Eligard
Category: GnRH & Reproductive
Mechanism of action: GnRH receptor super-agonist. Continuous receptor activation downregulates GnRH receptors after initial flare, suppressing LH/FSH.
Targets: GnRH receptor
Indications under research or approved: Prostate cancer, Endometriosis, Uterine fibroids, Central precocious puberty
Regulatory status (reference entry): FDA-approved (1985)
Half-life: ~3 hours (depot formulations release over 1-6 months)
Sequence notes: Nonapeptide pyroGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt — D-Leu at position 6 and ethylamide replace native Gly10.
Molecular weight (Da): 1209
Originator / sponsor: AbbVie / Tolmar
First reported: 1973

Primary References

Lupron Depot FDA label

Explore research articles about Leuprolide

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.